Strides Pharma receives approval from the USFDA for new antidepressant medication

Strides Pharma Science's subsidiary has gained USFDA approval to market a generic antidepressant, Fluoxetine Tabs. The medication is equivalent to Eli Lilly's Prozac tablets with a market size of USD 23.9 million. This approval enhances the company's presence in the Fluoxetine portfolio, alongside their existing approval for Fluoxetine capsules with a market size of USD 106 million. Fluoxetine is used for treating conditions like major depressive disorder and Obsessive Compulsive Disorder.

Strides Pharma Science on Tuesday said its subsidiary has received approval from the US health regulator to market a generic antidepressant medication.

The company's Singapore-based step-down wholly-owned subsidiary, Strides Pharma Global Pte Ltd, has received approval for Fluoxetine Tabs (10 and 20 mg) from the US Food & Drug Administration (USFDA), the drug firm said in a regulatory filing.

The company's product is therapeutically equivalent to Eli Lilly's Prozac tablets.

As per IMS, Fluoxetine tablets have a market size of USD 23.9 million.

This approval further strengthens the company's presence in the Fluoxetine portfolio, complementing the existing approval of Fluoxetine capsules, which has a market size of USD106 million, the Bengaluru based firm said.

Fluoxetine is used for the treatment of major depressive disorder (MDD) and Obsessive Compulsive Disorder (OCD) among others.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)